# OnCo record amivantamab (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/amivantamab/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "amivantamab" ;
  schema:name "Amivantamab"@en ;
  schema:description "A two-armed antibody that blocks EGFR and its escape partner MET, now first-line for EGFR-mutant lung cancer with lazertinib."@en ;
  schema:url <https://onco.cc/drugs/amivantamab/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Amivantamab> ;
  owl:sameAs <http://www.wikidata.org/entity/Q106957199> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Amivantamab>, <https://www.nice.org.uk/guidance/ta850>, <https://www.nice.org.uk/guidance/ta1122>, <https://www.nice.org.uk/guidance/ta1158> ;
  onco:status "approved" ;
  onco:modality "Bispecific antibody (EGFR×MET)" ;
  schema:alternateName "Rybrevant" ;
  onco:approval "US 2021: EGFR exon 20 insertion NSCLC", "US 2024: First-line EGFR-mutant NSCLC with lazertinib", "EU 2021: Exon 20; 1L with lazertinib Jan 2025", "England (NICE) 2022: Locally advanced or metastatic non-small-cell lung cancer with an EGFR exon 20 insertion after platinum-based chemotherapy: not recommended", "England (NICE) 2026: Untreated advanced EGFR mutation-positive non-small-cell lung cancer (exon 19 deletion or L858R), with lazertinib", "England (NICE) 2026: Untreated advanced non-small-cell lung cancer with an activating EGFR exon 20 insertion, with carboplatin and pemetrexed" ;
  onco:acceleratedApproval "US 2021-05-21: Treatment of adult patients with locally advanced or metastatic non small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA approved test, whose disease has progressed on or after platinum based chemotherapy" ;
  onco:acceleratedApprovalConfirmed "US 2024-03-01: Treatment of adult patients with locally advanced or metastatic non small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA approved test, whose disease has progressed on or after platinum based chemotherapy" ;
  onco:related <https://onco.cc/biomarkers/egfr-exon-19-deletion/>, <https://onco.cc/biomarkers/egfr-exon-20-insertion/> ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/egfr-mutant-nsclc/>, <https://onco.cc/cancers/met-altered-nsclc/>, <https://onco.cc/cancers/lung-cancer/> ;
  onco:technologies <https://onco.cc/technologies/bispecific-antibody/> ;
  onco:targets <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/met/> ;
  onco:companies <https://onco.cc/companies/johnson-johnson/> ;
  onco:terms <https://onco.cc/terms/cancer-drugs-fund/>, <https://onco.cc/terms/egfr-exon20-insertion/> ;
  onco:trials <https://onco.cc/trials/mariposa/>, <https://onco.cc/trials/nct05801029/>, <https://onco.cc/trials/nct05379595/>, <https://onco.cc/trials/nct05498428/>, <https://onco.cc/trials/nct05663866/>, <https://onco.cc/trials/nct06667076/>, <https://onco.cc/trials/nct07276399/>, <https://onco.cc/trials/nct04538664/>, <https://onco.cc/trials/nct07586202/>, <https://onco.cc/trials/nct06120140/>, <https://onco.cc/trials/nct06662786/>, <https://onco.cc/trials/nct06385080/>, <https://onco.cc/trials/nct06750094/>, <https://onco.cc/trials/nct05908734/>, <https://onco.cc/trials/nct05488314/>, <https://onco.cc/trials/nct07227025/>, <https://onco.cc/trials/nct04988295/>, <https://onco.cc/trials/chrysalis/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-mariposa-nejm-2024/> .